Founded in 2023 by former EMBL scientist Kashif Sadiq, DenovAI Biotech operates at the nexus of artificial intelligence and computational biophysics. DenovAI’s mission is to provide a transformative solution for antibody and protein biologic discovery. Its proprietary platform aims to reshape the landscape of biopharmaceuticals and harnesses de novo protein design, enabling the rapid identification of potential antibodies and small protein biologics. This approach significantly expedites the drug discovery process, making it more cost-effective and efficient. By shortening drug discovery timelines and reducing costs, DenovAI opens doors to novel antibody therapies for a wide range of diseases.
